

Indian Journal of Chemistry Vol. 60B, November 2021, pp. 1478-1489



# A review on synthesis and biological activity of Schiff Bases

Deepjyoti Dutta<sup>a</sup>, Nayan Kamal Bhattacharyya\*<sup>b</sup> & Joydeep Biswas<sup>b</sup>

<sup>a</sup>CSIR-North East Institute of Science and Technology, Jorhat 785 006, India <sup>b</sup>Sikkim Manipal Institute of Technology (Sikkim Manipal University), Majitar, Rangpo (Sikkim) 737 136, India

E-mail: nkamalbhatt@gmail.com; nayan.b@smit.smu.edu.in

Received 21 November 2020; accepted (revised) 20 September 2021

Schiff bases are versatile organic compounds, gaining importance day by day due to their wide applications. Schiff bases, containing imines or azomethine functional groups, are prepared by condensation of primary amines with carbonyl compounds or they may occur naturally in plants. They have lots of importance in industry and show numerous biological activities including antibacterial, antifungal, antiviral, anticancer, *etc.* The wide range of biological studies of the Schiff bases are now attracting the attention of researchers which can lead to the identification of promising lead compounds. This review consists of the recent developments and various methodologies to synthesize Schiff base as well as their biological activities covering the last 20 years.

Keywords: Amines, aldehydes, Schiff base, antibacterial, antifungal, antimalarial

Schiff Base (SB), a versatile compound discovered by chemist Hugo Schiff, is formed when condensation of primary amines with carbonyl compounds under specific reaction conditions<sup>1</sup>. They are also termed as imine or azomethine (-C=N-). SB ligands form more readily with aldehydes than ketones. Study on SB has been done due to its very flexible character and different structures. SBs form stable complexes with metal ions<sup>2-3</sup>. At very high temperature and in the presence of moisture many SBs show catalytic activity in various reactions. SB acts as an important intermediate in many enzymatic reactions which involves the interaction of an enzyme with carbonyl or an amino group of the substrate<sup>4-5</sup>. In the field of organic chemistry, SB shows large number of synthetic uses. It is widely used in organic compounds such as pigment, dyes, catalysts, intermediates and polymer stabilizers<sup>6</sup>.

Imines group can be found in a variety of natural and synthetic compounds which show diverse biological activities. SB also shows several biological properties including anti-inflammatory, antimalarial, antifungal, antibacterial, antiviral, anti-proliferative and antipyretic, *etc.*<sup>7-36</sup> SBs were showed antibacterial activity against some bacterial strains like *Acinetobacter baumannii*, *Bacillus subtilis*, *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella Pneumonia*, *M. tuberculosis*, *Micrococcus luteus*, *Micrococcus flavus*, *Mycobacterium phlei*, *Pseudomonas fluorescence*, Proteus vulgaris, Salmonella enteric, Staphylococcus aureus, Streptococcus epidermidis and S. pyogenes, etc.<sup>14-20</sup> SBs were reported to exhibit antifungal activity against fungal strains including Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Candida albicans, Candida tropicalis, Candida guilliermondii, Candida glabrata, Cryptococcus neoformans, Epidermophyton floccosum, Histoplasma capsulatum, Microsporum audouinii, Microsporum gypseum, Penicillium marneffei, Trichophyton mentagrophytes and Trichophyton rubrum, etc.<sup>21-24</sup>

In our review, we describe the various reported schemes to the synthesized of SBs. We also highlight the biological activities of SBs reported in the literature.

## Synthesis of Schiff Bases

Imine was prepared for the first time by Schiff in 19<sup>th</sup> century. He reported the synthesis of imines under azeotropic distillation. Dehydrating agents such as molecular sieves or magnesium sulphate are used to remove water from the system (Figure 1). Later, numerous methods have been reported for the



Figure 1 — General pathway for synthesis of a Schiff base

synthesis of imines. According to Chakraborti *et al.* 2004, the carbonyl compounds should be highly electrophilic and amines should be strongly nucleophilic for efficiency of the methods for synthesis of SB. A SB is formed when an aldehyde or ketone react with an amine by acid or base catalysis, or upon heating with the removal of water. Due to the

presence of effective conjugation, aromatic aldehydes form stable SBs in comparison to aliphatic aldehydes. Various techniques including microwave irradiation<sup>38–41</sup>, water suspension medium, solid-state synthesis, infrared irradiation and ultrasonication<sup>42-46</sup> have been reported. The different schemes of synthesis of SBs are listed in Table I.











1483



## **Biological activities of Schiff bases**

## Antibacterial activity

SBs have been reported to exhibit as significant antibacterial agents<sup>2</sup>. There are several synthetic or plant produced Schiff bases possess antibacterial activity. Shi et al., 2007 studied antimicrobial activity of synthesized 5-chlorosalicylaldehyde Shiff base derivatives (1-10) against P. fluorescence, E. coli, B. subtilis and S. aureus. Compounds (1-10) were found most active against P. fluorescence with MIC values 2.5-5.2 µg/mL, whereas reference drug kanamycin showed MIC value  $3.9 \,\mu\text{g/mL}$ . The Schiff bases 1, 2, 4-6 and 9-10 showed antibacterial activity against *E. coli* with MIC value 1.6–5.7  $\mu$ g/mL. Compound 9 showed antibacterial activity against B. subtilis (MIC value  $1.8 \,\mu\text{g/mL}$ ) whereas compounds 1 and 2 exhibited activity against S. aureus with MIC values 3.1 and 1.6  $\mu$ g/mL respectively<sup>14</sup>. Pandeya *et al.*, 1999a, 1999b reported antibacterial activity of Isatin-derived Schiff base 11 against twenty-eight pathogenic bacteria compared with sulfamethoxazole as reference drug. According to Hearn et al., 2004 the isoniazid-derived Schiff base 12 exhibited antibacterial activity against M. tuberculosis H37Rv with MIC value of 0.03 mg/L. Panneerselvam et al., 2005 tested antibacterial activity of morpholinederived Schiff bases (13-15) against S. aureus, M. luteus, S. epidermidis, B. cereus and E. coli. They reported that compound 13 showed activity S. aureus, M. luteus with MIC values 20 and 32 µg/mL, respectively. Compound 14 exhibited activity against S. epidermidis with MIC value 17 µg/mL. Moreover, compound 15 reported inhibition against B. cereus and E. coli with MIC values 21 and 16 µg/mL, respectively. According to Karthikeyan et al., 2006, Schiff bases with a 2,4-dichloro-5-fluorophenyl

compounds (16–19) were reported to hinder the bacterial growth against *S. aureus*, *E. coli*, *P. aeruginosa*, and *K. pneumonia* with MIC values from 6.3 to 12.5  $\mu$ g/mL, compared with reference drug Ciprofloxacin. The compounds are depicted in Figure 2.

The dimeric disulphide Schiff base derivatives 20-22 were studied for antimicrobial activity against A. baumannii, E. coli, K. pneumaniae, S. aureus, C. tropicalis, C. guilliermondii, C. albicans and C. glabrata by Disc diffusion method compared with standard Cefotaxime, Amoxicillin/clavulanic acid for antibacterial and Posaconazole for antifungal. SB (20) exhibited more inhibition against bacteria as compared to other SBs in which K. pneumaniae is the most sensitive bacterium. The fluorine containing SBs exhibited higher antimicrobial activity than bromine and chlorine containing SBs<sup>20</sup>. SBs (23-27) were studied for antimicrobial activity against pathogenic microorganisms by disc diffusion method with test sample 250 µg/disc. The results showed zones of inhibition for the SBs ranged from 0.9 to 3 cm for Gram positive bacteria, from 0.7 to 2.5 cm for gramnegative bacteria and from 0.6 to 2.4 cm for Candida which indicate better effect against gram positive bacteria than against gram negative and Candida<sup>21</sup>. A novel series of SBs 2-amino-4-(o-chloroanilino)-1.3-thiazole (28-37) exhibited promising antibacterial activity against S. aureus, B. subtilis, E. coli and K. pneumaniae. Cinnamyl chitosan SB was (38) showed to have antimicrobial activity against S. aureus, S. pyogenes, P. aeruginosa, P. vulgaris and Shigella. Salihovic et al., 2018 studied the in vitro antimicrobial activity of SBs (39-41) against bacteria S. aureus, Methicillin-resistant S. aureus: MRSA, B. subtilis, E. faecalis, S. enteric, P. aeruginosa,



Figure 2 — Structures of synthetic antibacterial Schiff bases

*E. coli*, and one yeast *C. albicans* by Agar Well Diffusion Method. SB (**39**) showed maximum inhibition against the microorganisms.

Madura hydroxylactone SBs (**42–47**) (Figure 3) isolated from *Actinomadura rubra* inhibited bacterial growth of *B. subtilis*, *M. flavus*, *Sa. lutea*, and *S. aureus*, with MIC values 0.2-3.1 µg/mL. They also showed very low activity against *M. phlei* or *P. vulgaris* with MIC value 50.0 µg/mL<sup>23-24</sup>.

## Antifungal activity

Both synthetic and naturally occurring Schiff bases reported promising antifungal activity (Figure 4). 2,4dichloro-5-fluorophenyl Schiff bases (16, 48–51) inhibit the growth of fungi against Aspergillus fumigatus, Aspergillus flavus, Penicillium marneffei, and *Trichophyton mentagrophytes* with MIC values range of  $6.3-12.5 \ \mu g/mL$ , compared with reference fluconazole<sup>19</sup>.

According to Echevarria et al., 1999, Piperonylderived Schiff bases (52-57) repressed the growth of fungi Trichophyton rubrum and Epidermophyton floccosum with MIC values 820-980 µM and 200-930 µM, respectively. The isatin-derived Schiff bases (11, 58-68) were found to have antifungal activity against *Microsporuma* udouinii and Microsporum gypseum with MIC values ranging from 2.4-9.7  $\mu$ g/mL and 1.2-9.7  $\mu$ g/mL, repectively<sup>15</sup>. Further, compounds (11, 58–68) also showed inhibition against Aspergillus niger, Candida albicans, Cryptococcus neoformans, E. floccosum, Histoplasma capsulatum and T. mentagrophytes at



Figure 3 — Structures of some antibacterial Schiff bases derived from plant

MIC values 10-79  $\mu$ g/mL<sup>16</sup>. Compounds **14** and **69** exhibited antifungal activity against *C. albicans* and *A. niger* conceded by treatment at 20 and 30  $\mu$ g/mL, repectively. Compound **70**, a natural product derived Schiff base reported antifungal activity against *C. albicans* and *C. neoformans* at 20  $\mu$ g/mL, whereas for free nystatin required a concentration of 10  $\mu$ g/mL. SB (**25**) showed moderate activity against *Candida* (24  $\mu$ g/mL) and could be a promising anti microbial agent<sup>21</sup>. The SBs 2-amino-4-(*o*-chloroanilino)-1,3-thiazole (**28-37**) exhibited promising antifungal activity against *C. albicans* and *A. niger*<sup>26</sup>. The hydrazone SB (**71**) synthesized by Pawaiya *et al.*, 2014 exhibited antifungal activity against *C. albicans*, *A. niger*, and *Penicillium* sp.



Figure 4 — Structures of some antifungal Schiff bases

## **Antimalarial activity**

A series of fifteen SBs derived from aromatic sulphonamides were tested as inhibitors of *Plasmodium falciparum* carbonic anhydrase enzyme compared with clinical drug acetazolamide (Figure 5). SBs **72-77** inhibited parasite activity with an affinity constant (KI) ranging from 0.54-1.23  $\mu$ g/mL against carbonic anhydrase enzyme<sup>27-28</sup>. SBs **78-80** exhibited good antimalarial activity against the tested 3D7 strain with IC<sub>50</sub> values ranging from 19.69 to

25.38  $\mu$ g/mL. SBs **81-86** exhibited antimalarial activity inhibiting the growth of this parasite (IC<sub>50</sub>, 2.28 - 26.9  $\mu$ g/mL<sup>29</sup>.

#### **Antiviral activity**

A 1-amino-3-hydroxyguanidine tosylate derived SB (87) was reported to exhibit antiviral activity against mouse hepatitis virus (MHV), by 50% inhibition in growth at concentrations of  $3.2 \ \mu M^{30}$  (Figure 6). Further, according to Sriram *et al.*, 2006



Figure 5 — Structures of some antimalarial Schiff bases



Figure 6 — Structures of some antiviral Schiff bases



Figure 7 — Structures of some antioxidant Schiff bases

the abacavir-derived Schiff bases (**88–98**) showed significant antiviral activity against HIV-1 in which compound **90** was the most potent Schiff base, being effective at 50 nM, could be a principal compound for new anti-HIV-1 (Figure 6). The new bis-Schiff bases of isatin, benzylisatin and 5-fluoroisatin (**99-110**) were reported having antiviral activity in human embryonic lung (HEL) and human epithelial (HeLa) cells and African green monkey kidney (Vero) cells<sup>31</sup>.

## Antioxidant activity

The SB (111) bearing N,N-dimethylamino benzaldehyde and 4-hydroxy benzaldehyde showed antioxidant activity with IC<sub>50</sub> value 50 mM compared with curcumin using 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay<sup>32</sup> (Figure 7). Vreese et al., 2016 studied antioxidant activity of thirteen new derivatives (112-124) bearing a  $\beta$ -enaminone by DPPH and the ferric reducing ability of plasma (FRAP) assays. SBs showed antioxidant activity by both tests (0.08-0.13% inhibition per mM by DPPH assay and 0.83–1.29 Trolox equiv. per mM by FRAP assay) compared with curcumin (0.15% inhibition per mM by DPPH assay and 1 Trolox equiv. per mM by  $\mathbf{FRAP}$  assay)<sup>33-34</sup>. The new enaminone analogues (125-132) exhibited antioxidant activities comparable to curcumin<sup>35-36</sup>.

# Conclusion

This article summarizes the working procedures of preparation of Schiff base since they have many important applications in organic chemistry. In this article we have also highlighted various biological activities of Schiff base.

# Acknowledgement

The authors thank Director, Sikkim Manipal Institute of Technology and Director, CSIR-North East Institute of Science and Technology for providing facilities to carry out this review work.

### References

- 1 Schiff H, Justus Liebigs Ann Chem, 131 (1864) 118.
- 2 Gur M, Yetlikaya S, Sener N, Ozkinali S, Baloglu C, Gokce H, Altunoglu Y C, demir S & Sener I, *J Mol struct*, 1219 (2020) 128570.
- 3 Selvaraj D &Krishnaveri R, Materials Today: Proceedings (2020).
- 4 Paquette L A & Benjamin W A, *Principles Mod Het Chem*, 318 (1968).
- 5 Xavier A & Srividhya N, IOSR-JAC, 7 (2014), 6.
- 6 Desai K R, Patel R B, Desai P S & Chikhalia K H, *J IndChem Soc*,80(2003).
- 7 Andiappan K, Sanmugam A, Deivanayagam E, Karuppasamy K, Kim H S & Vikraman D, Sci Rep, 8 (2018) 3054.
- 8 Niu M J, Li Z, Chang G L, Kong X J, Hong M & Zhang Q F, *PLoS One*, 10 (2015) e0130922.

- 9 Sheikh R A, Wani M Y, Shreaz S & Hashmi A A, Arab J Chem, 9 (2016) 743.
- 10 Shokohi-pour Z, Chiniforoshan H, Momtazi-borojeni AA & Notash B, *J Phytochem Photobiol*, 162 (2016) 34.
- 11 Hajrezaie M, Paydar M J, Moghadamtousi S Z, Hassandarvish P, Gwaram N S, Zahedifard N, Rouhollahi E, Karimian H, Looi C Y, Ali H M, Majid N A & Abdulla M A, *Sci World J*, 540463 (2014).
- 12 Xiao Y J, Diao Q C, Liang Y H & Zeng K, Braz J Med Biol Res, 50 (2017) e6390.
- 13 Hong M, Geng H, Niu M, Wang F, Li D, Liu J & Yin H, *Eur J Med Chem*, 86, (2014) 550.
- 14 Shi L, Ge H M, Tan S H, Li H Q, Song Y C & Zhu H L, Eur J Med Chem, 42 (2007) 558.
- 15 Pandeya S N, Sriram D, Nath G, de Clercq E. IL *Farmaco*, 54 (1999) 624.
- 16 Pandeya S N, Sriram D, Nath G & de Clercq E, *Eur J Pharm* Sci, 9 (1999) 25.
- 17 Hearn M J, Cynamon M H, J Antimicrob Chemother, 53 (2004) 185.
- 18 Panneerselvam P, Nair R R, Vijayalakshmi G, Subramanian E H, Sridhar S K, Eur J Med Chem, 40 (2005) 225.
- 19 Karthikeyan M S, Prasad D J, Poojary B, Bhat K S, Holla B S, Kumari N S, *Bioorg Med Chem*, 14 (2006) 7482.
- 20 Durmus S, Dalmaz A, Dulger G, Kadioglu D B, *The EuroBiotech J*, 1 (2017) 230.
- 21 Matar S A, Talib W H, Mustafa M S, AlDamen M A, *Arabian J Chem*, 8 (2015) 850.
- 22 Salihovic M, Pazalja M, Mahmutovic-Dizdarevic I, Jerkovic-Mujkic A, Suljagic J, Spirtovic-Halilovic S & Sapcanin A, *Rasayan J Chem*, 11 (2018) 1074.
- 23 Paulus E F, Dornberger K, Werner W & Fenske D, Acta Crystallograph, 50 (1994) 2064.
- 24 Heinisch L, Roemer E, Jutten P, Haas W, Werner W & Mollmann U J, *Antibiotics (Tokyo)* 52 (1999) 1029.
- 25 Echevarria A, Nascimento MG, Geronimo V, Miller J & Giesbrecht A, J Braz Chem Soc, 10 (1999) 60.
- 26 Eldin M S M, Hashem A I, Omer A M & Tamer T M, Int JAdv Res, 4 (2015) 741.
- 27 Krungkrai SR, Suraveratum N, Rochanakij S & Krungkrai J, Int J Parasitol, 31 (2001) 661.
- 28 Sharma M, Chauhan K, Srivastava RK, Singh S V, Srivastava K & Saxena JK, *Chem Biol Drug Des*, 84 (2014) 175.
- 29 Fonkui TY, Ikhile MI, Ndinteh D T &Njobeh PB, *Trop J Pharma Res*, 17 (2018) 2507.
- 30 Sriram D, Yogeeswari P, Myneedu N S, Saraswat V, Bioorg Med Chem Lett, 16 (2006) 2127.
- 31 Jarrahpour A, Khalili A, Clercq ED, Salmi C, Brunel J M, *Molecules*, 12 (2007) 1720.
- 32 Karki R, Rao GK, Gupta A, Mariappan G, Adhikari S, J Applied Pharma Sci, 3 (2013) 093.
- 33 Revathi R, Ananth D A, Rameshkumar A &Sivasudha T, *Asian J Chem*, 27 (2015), 1489.
- 34 Vreese R D, Grootaert C, Dhoore S, Theppawong A, Damme S V,Bogaert M V, Camp J V &Dhooghe M, *Eur J Med Chem*, 123 (2016) 727.
- 35 Theppawong A, Vreese R D, Vannecke L, Grootaert C, Camp J V &Dhooghe M, *Bioorg Med Chem Lett*, 26 (2016) 5650.

- 36 Omidi S & Kakanejadifard A, RSC Adv, 10 (2020) 30186.
- 37 Chakraborti A K, Bhagat S & Rudrawar S, Tetrahedron Lett, 45 (2004) 7641.
- 38 Zhang S H & Feng C, J Mol Struct, 977 (2010) 62.
- 39 Neochoritis CG, Zarganes-Tzitzikas T, Tsoleridis CA, Stephanidou-Stephanatou J, Kontogiorgis CA, Hadjipavlou-Litina DJ, *Eur J Med Chem*, 46 (2011) 297.
- 40 Thaker B T &Barvalia R S,Spectrochim Acta A Mol BiomolSpectros, 84 (2011) 51.
- 41 Maurya M R, Saini N & Avecilla F, *InorganicaChim Acta*, 438 (2015) 168.
- 42 Schmeyers J, Toda F, Boy J &Kaupp G, J Chem Soc Perkin Trans, 2 (1998) 989.
- 43 Gopalakrishnan M, Sureshkumar P, Kanagarajan V, Thanusu J & Govindaraju R, *J Chem Res*, 5 (2005) 299.
- 44 Gopalakrishnan M, Sureshkumar P, Kanagarajan V &Thanusu J, Res Chem Intermed, 33 (2007) 541.
- 45 Gedye R, Smith F, Westaway K, Ali H, Baldisera L & Laberge L, *Tetrahedron Lett*, 27 (1986) 279.
- 46 Giguere RJ, Bray TL, Duncan S M & Majetich G, *Tetrahedron Lett*, 27 (1986) 4945.
- 47 Ashraf M A, Mahmood K & Wajid A, *Int Proceeding Chem Biol Env Eng*, 10 (2011).
- 48 Ibrahim MN, Sharif SEA, E-J Chem, 4 (2007) 531.
- 49 Al-Garawi ZSM, Tomi IHR, Al-Daraji AHR, *E-J Chem*, 9 (2012) 962.
- 50 Bhagat S, Sharma N & Chundwat TS, J Chem, (2013) 1.
- 51 Jisha MJ, Isac SR, Int J Sci Res Pub, 7 (2010) 10.
- 52 More G, Raut D, Aruna K, Bootwala S, *J Saudi Chem Soc*, 21 (2017) 954.
- 53 El-Nawawy MA, Farag RS, Sbbah I A& Abu-Yamin AAM, New York Sci J, 4 (2011).
- 54 Kapadnis K H, Jadhav S P, Patil A P, Hiray AP, World J Pharm Pharma Sci, 5 (2016) 1055.
- 55 Dayma V, Sharma P,Salvi P, Rathore M K & Baroliya PK, Int J Res advent Technol,6 (2018).
- 56 Yang ZH, Wang LX, Zhou Z H, Zhou Q L & Tang CC, *A symmetry*, (2001) 12.
- 57 Pai N R &Waghmode KT, *Der Pharma Chemica*, 4 (2012) 622.
- 58 Zarei M &Jarrahpour A, Iran J SciTechnol, A3 (2011) 235.
- 59 AL-Shimary BM, Nat J Chem, 31 (2008) 428.
- 60 Mistry K & Desai KR, Ind J Chem, 44B (2005) 1452.
- 61 Ronad MP, Noolvi MN, Sapkal S, Dharbhamulla S, Maddi V S, *Eur J Med Chem*, 45 (2010) 85.
- 62 Zeng Z, Zhao G, Gao P, Tang H, Chen B, Zhou Z, Tang C, *Catal Commun*, 8 (2001) 1443.
- 63 Pawaiya A, Pawaiya P, Rajput S, Agrawal M C & Bhatnagar RK, *Int J Current Res*, 6 (2014) 8423.
- 64 Vass A, Dudas J & Varma R S, *Tetrahedron Lett*, 40 (1999) 4951.
- 65 Tanaka K & Shiraishi R, Green Chem, 2 (2000) 272.
- 66 Varma R S, Dahiya R & Kumar S,*Tetrahedron Lett*, 38 (1997) 2039.
- 67 Andrade CKZ, Takada SCS, Alves LM, Rodrigues JP, Suarez P A Z & Brandao RF, *Synlett*, 12 (2004) 2135.
- 68 Vazquez MA, Landa M, Reyes L, Miranda R, Tamariz J & Delgado F, *Synth Commun*, 34 (2004) 2705.